GWOXI Stem Cell Applied Technology Co., Ltd. was established in 2004, on basis of its applied stem cell technology to innovate new applications in regenerative and preventive medicines, set up health-examination platforms, and develop innovative stem cell drug. GWOXI has not only been cultivating in applied stem cell research for a long time, but also bringing together resources in industry, government, academics and medicine in hoping to benefit all human being to the most extend.In 2010, GWOXI was granted for its “applied stem cell technology in treating liver cirrhosis/fibrosis” by National Science Council of Taiwan to establish a GTP-standard stem cell R&D center in Biomedical Science Park in Hsinchu Country. GWOXI then became one of government-support biotechnology and pharmaceutical companies after passing through the Act for the Development of Biotech and New Pharmaceuticals Industry under Industrial Development Bureau of Ministry of Economic Affairs in 2012. Three new stem cell drugs were successfully promoted to clinical trials by June 2020. In 2019, GWOXI successfully moved into National Biotechnology Research Park (NBRP) for the development of advanced medical products and currently is building a PIC/S GMP certified stem cell medicine factory in Hsinchu Biomedical Park, which is expected to be a milestone in the production of drugs in the future.